Clinical Testing Guidance for Tuberculosis: Interferon Gamma Release Assay

The TB blood test (interferon gamma release assay [IGRA]) mixes a patient’s blood samples with peptides that simulate antigens derived from TB bacteria and with controls. The TB antigens were chosen because they are found in M. tuberculosis complex, including M. bovis, but they are absent from BCG and from the majority of other mycobacteria.

In most people infected with TB bacteria, specific immunity develops within six to eight weeks. Then, some white blood cells can respond to the simulated TB antigens releasing interferon-gamma (IFN-γ). The tests measure the level of IFN-γ response. Control substances are used for comparison purposes to help verify test results and to determine a person’s background level of IFN-γ.

Keep Reading: Testing for Tuberculosis: Blood Test

The U.S. Food and Drug Administration (FDA) has approved these two TB blood tests that are commercially available in the United States:

Comparison of the QFT-Plus and the T-Spot

Comparison of the QFT-Plus and the T-Spot TB blood tests
Characteristics QFT-Plus T-Spot
Processing time Within 16 hours (whole blood) Within 8 to 32 hours (blood cells)
M. tuberculosis antigens ESAT-6 and CFP-10 ESAT-6 and CFP-10
Measurement IFN-γ concentration Number of IFN-γ producing cells (spots)
Possible results Positive, negative, indeterminate Positive, negative, invalid, borderline

Advantages and disadvantages of the TB blood test (compared to the TB skin test)

The TB blood tests serve the same purpose as the tuberculin skin test, but they have functional and diagnostic differences.

Advantages

Disadvantages

Determining an approach

Reminder‎

Providers should review the FDA-approved product labeling for the IGRA for information about the test characteristics, the precautions, and recommendations about how to interpret results.

CDC has resources to help health care providers talk to patients about TB testing and treatment.

Health care providers are encouraged to use TB blood tests to test for TB infection. TB blood tests are the preferred method of testing for:

Health care providers should take into account the following factors when considering the TB blood test for a patient:

Age

Current CDC guidelines recommend the TB skin test as the method of testing for children younger than 5 years of age, while noting that some experts use TB blood tests in younger children. Health care providers may choose to consult the American Academy of Pediatrics (AAP) guidance 1 on the use of TB blood tests in children. The collection of a sufficient blood sample can be a practical barrier to testing very young children with a TB blood test.

Vaccinations

Live virus vaccination

Vaccination with live viruses, including measles, mumps, rubella, oral polio, varicella, and yellow fever may interfere with TB blood test reactions. For persons scheduled to receive a TB blood test, testing should be done:

Other vaccinations

Vaccination with inactivated viruses does not interfere with TB blood test reactions.

COVID-19 vaccination should not be delayed because of testing for TB infection. TB blood tests are not expected to affect the safety or the effectiveness of COVID-19 vaccines. Testing for TB infection with a TB blood test can be done before, during, or after a COVID-19 vaccination visit.

TB history

TB blood tests (and TB skin tests) should not be performed on people who have written documentation of a previous positive TB test result (TB blood test or TB skin test) or treatment for TB disease. Most people who have a positive TB test result will continue to have a positive test result. Additional TB blood tests will probably not contribute to medical care, regardless of the result.

Testing guidelines

Health care providers should be properly trained on how to conduct a TB blood test. Health care providers should read the instructions from the manufacturer and follow the steps below:

  1. Confirm arrangements for testing in a qualified laboratory. Some laboratories may only offer one type of TB blood test, or none at all.
  2. Arrange for delivery of the blood sample to the laboratory within the time the laboratory specifies to ensure testing of samples containing viable blood cells.
  3. Draw a blood sample from the patient according the test manufacturer's instructions. Note that the instructions for blood collection and initial processing are different for the two TB blood tests.
  4. Schedule a follow-up appointment for the patient to receive test results.
  5. Provide follow-up evaluation and treatment as needed based on test results.

How to interpret test results

Interpretation of TB blood test results depends on the test being used:

QFT-Plus results are based on the amount of IFN-γ that is released in response to the antigens and to the control substances after the blood has been incubated these substances.

T-Spot results are based on comparing the number of IFN-γ producing cells (spots) produced after the blood has been incubated with these substances.

Laboratories should provide both the qualitative and quantitative results: